168 related articles for article (PubMed ID: 15250833)
1. Salivary secretory leukocyte protease inhibitor increases in HIV infection.
Lin AL; Johnson DA; Stephan KT; Yeh CK
J Oral Pathol Med; 2004 Aug; 33(7):410-6. PubMed ID: 15250833
[TBL] [Abstract][Full Text] [Related]
2. Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues.
Wahl SM; Worley P; Jin W; McNeely TB; Eisenberg S; Fasching C; Orenstein JM; Janoff EN
Am J Pathol; 1997 Apr; 150(4):1275-84. PubMed ID: 9094984
[TBL] [Abstract][Full Text] [Related]
3. Endogenous mucosal antiviral factors of the oral cavity.
Shugars DC
J Infect Dis; 1999 May; 179 Suppl 3():S431-5. PubMed ID: 10099113
[TBL] [Abstract][Full Text] [Related]
4. The effect of parotid salivary flow rate on the levels of salivary antimicrobial proteins in patients with Sjögren's syndrome.
Zipp MM; Yasbin L; al-Hashimi I
Quintessence Int; 1999 Oct; 30(10):700-5. PubMed ID: 10765854
[TBL] [Abstract][Full Text] [Related]
5. Enhanced secretory leukocyte protease inhibitor in human immunodeficiency virus type 1-infected patients.
Baqui AA; Meiller TF; Falkler WA
Clin Diagn Lab Immunol; 1999 Nov; 6(6):808-11. PubMed ID: 10548568
[TBL] [Abstract][Full Text] [Related]
6. Endogenous salivary inhibitors of human immunodeficiency virus.
Shugars DC; Alexander AL; Fu K; Freel SA
Arch Oral Biol; 1999 Jun; 44(6):445-53. PubMed ID: 10401522
[TBL] [Abstract][Full Text] [Related]
7. Increased serum concentrations of secretory leukoprotease inhibitor in patients with primary Sjögren's syndrome.
Maruyama M; Sugiyama E; Hori T; Murayama R; Nakazaki S; Yamashita N; Kobayashi M
In Vivo; 1998; 12(5):535-8. PubMed ID: 9827363
[TBL] [Abstract][Full Text] [Related]
8. [Amylase activity, protein concentration and flow rate of unstimulated human parotid saliva (author's transl)].
Arglebe C; Opaitz M; Chilla R
Laryngol Rhinol Otol (Stuttg); 1979 Sep; 58(9):700-5. PubMed ID: 522590
[TBL] [Abstract][Full Text] [Related]
9. Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I.
Wahl SM; McNeely TB; Janoff EN; Shugars D; Worley P; Tucker C; Orenstein JM
Oral Dis; 1997 May; 3 Suppl 1():S64-9. PubMed ID: 9456660
[TBL] [Abstract][Full Text] [Related]
10. IgA subclasses in HIV disease: dichotomy between raised levels in serum and decreased secretion rates in saliva.
Sweet SP; Rahman D; Challacombe SJ
Immunology; 1995 Dec; 86(4):556-9. PubMed ID: 8567021
[TBL] [Abstract][Full Text] [Related]
11. Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type 1-infected persons.
Chattopadhyay A; Gray LR; Patton LL; Caplan DJ; Slade GD; Tien HC; Shugars DC
Infect Immun; 2004 Apr; 72(4):1956-63. PubMed ID: 15039315
[TBL] [Abstract][Full Text] [Related]
12. Impact of aging on human salivary gland function: a community-based study.
Yeh CK; Johnson DA; Dodds MW
Aging (Milano); 1998 Oct; 10(5):421-8. PubMed ID: 9932146
[TBL] [Abstract][Full Text] [Related]
13. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro.
McNeely TB; Dealy M; Dripps DJ; Orenstein JM; Eisenberg SP; Wahl SM
J Clin Invest; 1995 Jul; 96(1):456-64. PubMed ID: 7615818
[TBL] [Abstract][Full Text] [Related]
14. Analysis of secretory leukocyte protease inhibitor (SLPI) in bronchial secretions from patients with hypersecretory respiratory diseases.
Kouchi I; Yasuoka S; Ueda Y; Ogura T
Tokushima J Exp Med; 1993 Jun; 40(1-2):95-107. PubMed ID: 8105562
[TBL] [Abstract][Full Text] [Related]
15. Secretory leukocyte protease inhibitor (SLPI): oxidation of SLPI does not explain its variable anti-HIV activity.
Konopka K; Shine N; Pretzer E; Düzgüneş N
J Dent Res; 1999 Dec; 78(12):1773-6. PubMed ID: 10598905
[TBL] [Abstract][Full Text] [Related]
16. Identification of SLPI (secretory leukocyte protease inhibitor) in human mast cells using immunohistochemistry and in situ hybridisation.
Westin U; Polling A; Ljungkrantz I; Ohlsson K
Biol Chem; 1999 Apr; 380(4):489-93. PubMed ID: 10355635
[TBL] [Abstract][Full Text] [Related]
17. Secretory leukocyte protease inhibitor is a novel inhibitor of fibroblast-mediated collagen gel contraction.
Sumi Y; Muramatsu H; Hata K; Ueda M; Muramatsu T
Exp Cell Res; 2000 Apr; 256(1):203-12. PubMed ID: 10739667
[TBL] [Abstract][Full Text] [Related]
18. [The clinical study on secretory leukoprotease inhibitor (SLPI) in sera of patients with various pulmonary diseases].
Sugimoto H; Hashimoto N; Ameshima S; Gejyo F; Ishizaki T; Miyabo S
Rinsho Byori; 1995 Dec; 43(12):1267-72. PubMed ID: 8569039
[TBL] [Abstract][Full Text] [Related]
19. Salivary flow rate, protein and electrolyte concentrations in chronic alcoholic patients.
Scott J; Woods K; Baxter P
J Biol Buccale; 1988 Dec; 16(4):215-8. PubMed ID: 3243776
[TBL] [Abstract][Full Text] [Related]
20. Production of secretory leucocyte protease inhibitor (SLPI) in human pancreatic beta-cells.
Nyström M; Bergenfeldt M; Ljungcrantz I; Lindeheim A; Ohlsson K
Mediators Inflamm; 1999; 8(3):147-51. PubMed ID: 10704052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
